|
|
News Breaks | | | | October 3, 2012 | | 08:13 EDT |  | SRPT | Sarepta Therapeutics price target raised to $38 from $11 at Piper Jaffray
Piper Jaffray significantly raised its price target for Sarepta Therapeutics after Eteplirsen showed statistically significant increases in both Dystrophin-positive fibers and 6-Minute Walk Test. Piper expects the FDA may approve Eteplirsen next year, which is two years ahead of its prior expectations. The firm reiterates an Overweight rating on the stock, which is currently up 126%, or $18.94, to $33.93 in pre-market trading. | |
|
News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. |
|
|
| May 21, 2013 | | 07:34 EDT |  | SRPT | UBS to host a conference
 Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT | | SRPT | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 9, 2013 | | 12:21 EDT |  | SRPT | Sarepta climbs after saying documents to be submitted this month
Subscribe for More Information | | | 07:29 EDT |  | SRPT | Sarepta reports Q1 EPS (41c), consensus (62c)
Reports Q1 revenue $4.5M, consensus $5.85M. | |
|
|
|
|
|
|
